Journal article

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

Fiona Tea, Joseph A Lopez, Sudarshini Ramanathan, Vera Merheb, Fiona XZ Lee, Alicia Zou, Deepti Pilli, Ellis Patrick, Anneke van der Walt, Mastura Monif, Esther M Tantsis, Eppie M Yiu, Steve Vucic, Andrew PD Henderson, Anthony Fok, Clare L Fraser, Jeanette Lechner-Scott, Stephen W Reddel, Simon Broadley, Michael H Barnett Show all



Over recent years, human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have been associated with monophasic and relapsing central nervous system demyelination involving the optic nerves, spinal cord, and brain. While the clinical relevance of MOG Ab detection is becoming increasingly clear as therapeutic and prognostic differences from multiple sclerosis are acknowledged, an in-depth characterization of human MOG Ab is required to answer key challenges in patient diagnosis, treatment, and prognosis. Herein, we investigated the epitope, binding sensitivity, and affinity of MOG Ab in a cohort of 139 and 148 MOG antibody-seropositive children and adults (n = 287 patients..

View full abstract


Funding Acknowledgements

This work was supported by the National Health and Medical Research Council (Australia), Multiple Sclerosis Research Australia, and the Sydney Research Excellence Initiative 2020 (The University of Sydney, Australia). We thank all the patients and family members who participated in this study. We thank Dr. Maggie Wang and Dr. Suat Dervish for our use of the Flow Cytometry Core Facility of the Westmead Research Hub (Australia) supported by the Cancer Institute New South Wales, the National Health and Medical Research Council, and the Ian Potter Foundation. We thank David Campbell and Sue Culican at the ICPMR, Westmead Hospital, for their contribution to the fixed biochip assay, and Ms. Liz Barnes for her assistance with statistical analyses. We thank Dr. Yves Dieffenbach for her expertise in the purification of native-MOG<SUP>1-117</SUP>.